Inhibrx Biosciences Receivables

Inhibrx Biosciences (INBX) currently reports a receivables of $130K as of June 2026. That compares with $970K in the prior-year period — down 86.3% year over year. Use the charts on this page to explore Inhibrx Biosciences's receivables history and peer comparisons.

Inhibrx Biosciences's receivables decreased from $970K to $130K — a 86.3% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Inhibrx Biosciences reported $130K in receivables as of June 2026. That compares with $970K in the prior-year period — down 86.3% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $130K, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Inhibrx Biosciences, and consider following INBX for alerts when major investors trade the stock.

Inhibrx Biosciences is classified in the Healthcare sector. On receivables, it currently shows $130K. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing INBX with unrelated industries.